Lipoprotein(a): what your result means.

Lipoprotein(a), or Lp(a), is an LDL-like particle with an extra apolipoprotein(a) protein attached. Your level is set almost entirely by your genes, stays stable for life, and is carried at elevated levels by roughly 1 in 5 people, most of whom have never been tested.

Why Lipoprotein(a) matters

Lp(a) is both atherogenic and pro-thrombotic, and Mendelian randomisation studies show it causally drives heart attack and calcific aortic stenosis. Because one test reveals lifetime exposure, the European Atherosclerosis Society recommends every adult measure it at least once. Read our full deep-dive: Lipoprotein(a): the genetic heart risk one test can find.

Associated risks when out of range: Premature cardiovascular disease. Calcific aortic stenosis. Residual risk despite optimal LDL/ApoB.

What the clinical evidence shows

The evidence base behind how the HodieLabs Evidence-Based Clinical Library interprets Lipoprotein(a), from randomised trials, prospective cohorts and genetic (Mendelian randomisation) studies. Full citations in the reference list below.

• Copenhagen General Population Study (Kamstrup et al. JAMA 2009): genetically elevated Lp(a) was associated with a doubling to tripling of myocardial infarction risk at the highest levels, and because the exposure was genetic, the association cannot be explained by lifestyle confounding.
• UK Biobank analysis (Patel et al. ATVB 2021): across more than 400,000 participants, cardiovascular risk rose linearly with Lp(a), approximately 11% higher risk per 50 nmol/L, with no safe plateau.
• Genetic analysis of aortic stenosis (Thanassoulis et al. NEJM 2013): inherited LPA gene variants were the strongest genetic driver of aortic valve calcification identified, establishing Lp(a) as the leading causal risk factor for calcific aortic stenosis.
• EAS consensus statement (Kronenberg et al. European Heart Journal 2022): the definitive synthesis of 40+ years of evidence: Lp(a) is a causal, independent risk factor; every adult should be tested at least once, with cascade screening of relatives when elevated.
• Phase 2 drug trials (Tsimikas et al. NEJM 2020; O'Donoghue et al. NEJM 2022): antisense (pelacarsen) and siRNA (olpasiran) therapies lowered Lp(a) by 80–95%+; large phase 3 cardiovascular outcome trials are underway.

Evidence-based reference ranges

The HodieLabs Evidence-Based Clinical Library interprets Lipoprotein(a) against published clinical authority standards, never arbitrary "optimal" ranges. Measured in nmol/L:

Band	Range (nmol/L)
Optimal	<75 nmol/L
Borderline	75–125 nmol/L
High	>125 nmol/L

Clinical interpretation

• Genetically determined. Levels are stable over a lifetime and unresponsive to lifestyle changes.
• Lp(a) is both atherogenic and pro-thrombotic; it amplifies cardiovascular risk from other lipid abnormalities.
• Measure once; if elevated, it reframes the urgency of controlling modifiable risk factors (LDL, BP, inflammation).
• ESC/EAS explicitly recommends measuring Lp(a) at least once in adult life to identify inherited high-risk individuals.

What improves it: the evidence-based levers

• Aggressive ApoB lowering
• Consider specialist referral if very high
• Consider CAC discussion

Recommended testing frequency: Annual, as part of a comprehensive panel. Single markers are always interpreted in context.

How Lipoprotein(a) testing works at HodieLabs

Lipoprotein(a) is measured in every Health Blueprint at our Melbourne Preventative Health & Longevity Clinic, interpreted by a doctor against the guideline-cited ranges above and tracked over time through your HodieLabs membership.

References

1. Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925–3946.
2. Kamstrup PR, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–2339.
3. Patel AP, et al. Lp(a) concentrations and incident atherosclerotic cardiovascular disease: analysis in the UK Biobank. Arterioscler Thromb Vasc Biol. 2021;41:465–474.
4. Thanassoulis G, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–512.
5. Tsimikas S, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244–255.
6. O'Donoghue ML, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387:1855–1864.

This page is general information from the HodieLabs Evidence-Based Clinical Library, not medical advice. Speak with your GP about what testing and care is appropriate for you.